ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial

NCT06664879 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
3
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

M.D. Anderson Cancer Center

Collaborators